Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder

Human Psychopharmacology

Volumn 20, Issue 1, 2005, Pages 3-13

  Steiner, Meir ^a   Allgulander, Christer ^b   Ravindran, Arun ^c   Kosar, Hana ^d   Burt, Tal ^d,e   Austin, Carol ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TORONTO   (Canada)

^d PFIZER INC   (United States)

^e Department of Psychiatry ^*  (United States)

Author keywords

Anxiety; Gender differences; Sertraline

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HEALTH STATUS; HUMAN; HYPERHIDROSIS; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA; ONSET AGE; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MALE; SERTRALINE; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 13644265307     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.648     Document Type: Article

References (57)

1. Allgulander C, Dahl AA, Austin C, et al. 2004. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161: 1642-1649.
2. Allgulander C, Hackett D, Salinas E. 2001. Venlafaxine-XR extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179: 15-22.
3. Ansseau M, Dierick M, Buntinkx F, et al. 2004. High prevalence of mental disorders in primary care. J Affect Disord 78: 49-55.
4. Blazer DG, Hughes D, George LK, Swartz M, Boyer R. 1991. Generalized anxiety disorder. In Psychiatric Disorders in America, Robins LH, Regier DA (eds). Free Press: New York; 180-203.
5. Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al. 1993. Psychiatric comorbidity in patients with GAD. Am J Psychiatry 150: 1216-1218.
6. Brown G, Harris T, Eales M. 1996. Social factors and comorbidity of depressive and anxiety disorders. Br J Psychiatry (Suppl. June): 50-57.
7. Brown TA, Barlow DH. 1992. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 60: 835-844.
8. Carter RM, Wittchen H-U, Pfister H, Kessler RC. 2001. One year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 13: 78-88.
9. Cutler NR, Sramek JJ, Keppel-Hesselink JM, et al. 1993. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 13: 429-437.
10. Davidson JRT, DuPont RL, Hedges D, Haskins JT. 1999. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60: 528-535.
11. Endicott J, Nee J. 1997. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 33: 13-16.
12. Endicott J, Nee J, Harrison W, Blumenthal R. 1993. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29: 321-326.
13. Fehr C, Szegedi A, Anghelescu I, Klawe C, Hiemke C, Dahmen N. 2000. Sex differences in allelic frequencies of the 5-HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study. Psychiatr Genet 10: 59-65.
14. Feighner JR. 1987. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 48 (Suppl. : 3-6.
15. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. 2000. Efficacy of venlafaxine-XR extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283: 3082-3088.
16. Gorman J. 2002. Treatment of generalized anxiety disorder. J Clin Psychiatry 63 (Suppl. 8): 17-23.
17. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. Publication (ADM); 276-338. National Institute of Mental Health-US Dept of Health, Education, and Welfare: Washington, DC.
18. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
19. Hoehn-Saric R. 1998. Psychic and somatic anxiety: worries, somatic symptoms and physiological changes. Acta Psychiatr Scand Suppl 393: 32-38.
20. Hoehn-Saric R, McLeod DR, Zimmerli WD. 1988. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms. J Clin Psychiatry 49: 293-301.
21. Howell HB, Brawman-Mintzer O, Monnier J, Yonkers KA. 2001. Generalized anxiety disorder in women. Psychiatry Clin North Am 24: 165-178.
22. Hunt C, Issakidis C, Andrews G. 2002. DSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Well-Being. Psychol Med 32: 649-659.
23. Judd LL, Kessler RC, Paulus MP, et al. 1998. Comorbidity as a fundamental feature of generalized anxiety disorder: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand 98 (Suppl. 393): 6-11.
24. Katz IR, Reynolds CF, Alexopoulos GS, Hackett D. 2002. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatrics Society 50: 18-25.
25. Kendler KS, Walters EE, Neale MC, et al. 1995. The structure of genetic and environmental risk factors for six major psychiatric disorders in women: phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry 52: 374-383.
26. Kessler RC, DuPont RL, Berglund P, Wittchen HU. 1999. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156: 1915-1923.
27. Kessler RC, McGonagle KA, Zhao S, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19.
28. Lerer B, Macciardi F. 2002. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 5: 255-275.
29. Lewinsohn P, Gotlib IH, Lewinsohn M, et al. 1998. Gender differences in anxiety disorders and anxiety symptoms in adolescents. J Abnorm Psychol 107: 109-117.
30. Massion AO, Warshaw MG, Keller MB. 1993. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 150: 600-607.
31. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
32. Montgomery SA, Sheehan DV, Meoni P, et al. 2002. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 36: 209-217.
33. Noyes R, Jr, Woodman C, Garvey MJ, et al. 1992. Generalized anxiety disorder vs. panic disorder: distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis 180 369-379.
34. Ormel J, VonKorff M, Üstun TB, et al. 1994. Common mental disorders and disability across cultures: results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA 272: 1741-1748.
35. Pecknold JC, Maras M, Howarth BG, et al. 1989. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 34: 766-771.
36. Pollack MH, Rapaport MH, Clary CM, et al. 2000. Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry 61: 922-927.
37. Pollack MH, Zaninelli R, Goddard A, et al. 2001. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62 350-357.
38. Rausch JL, Johnson ME, Fei YJ, et al. 2002. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 51: 723-732.
39. Rickets K, Downing R, Schweizer E, Hassman H. 1993. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50: 884-895.
40. Rickels K, Pollack MH, Sheehan DV, Haskins JT. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157: 968-974.
41. Rickels K, Schweizer E, DeMartinis N, et al. 1997. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 17: 272-277.
42. Rickels K, Zaninelli R, McCafferty J, et al. 2003. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160: 749-756.
43. Robins LN, Regier DA. 1991. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. The Free Press: New York.
44. Rogers MP, Warshaw MG, Goisman RM, et al. 1999. Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorder. Depress Anxiety 10: 1-7.
45. Ronfeld FA, Tremaine LM, Wilner KD. 1997. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32 (Suppl. 1): 22-30.
46. Rynn MA, Siqueland L, Rickels K. 2001. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 158: 2008-2014.
47. Serretti A, Lilli R, Smeraldi E. 2002. Pharmacogenetics in affective disorders. Eur J Pharmacol 438: 117-128.
48. Sheehan DV, Lecrubier Y, Sheehan KH, et al. 1998. The Mini International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl. 20): 22-33.
49. Strand M, Hetta J, Rosen A, et al. 1990. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 51(Suppl.): 40-45.
50. Wittehen H-U, Carter RM, Pfister H, et al. 2000. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15: 319-328.
51. Wittchen H-U, Kessler RC, Beesdo K, et al. 2002. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl. 8): 24-34.
52. Wittchen H-U, Krause P, Hoyer J, et al. 2001. Prevalence and correlates of GAD in primary care. Fortschr Med Orig 119(Suppl. 1): 17-25.
53. Wittchen H-U, Zhao S, Kessler RC, Eaton WW. 1994. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51: 355-364.
54. Yonkers KA, Dyck IR, Warshaw M, Keller MB. 2000. Factors predicting the clinical course of generalised anxiety disorders. Br J Psychiatry 176: 544-549.
55. Yonkers KA, Warshaw MG, Massion AO, Keller MB. 1996. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 168: 308-313.
56. Yonkers KA, Zlotnick C, Allsworth J, et al. 1998. Is the course of panic disorder the same in women and men? Am J Psychiatry 155: 596-602.
57. Zigmond A, Snaith RP. 1983. The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361-370.